Impact BioMedical, INC. Accounts Payable
Impact BioMedical, INC. (IBO) had Accounts Payable of $467.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-07
- 2026-06-30: Accounts Payable, Current $467.00K.
- 2026-03-31: Accounts Payable, Current $374.00K.
- 2025-12-31: Accounts Payable, Current $347.00K.
- 2025-09-30: Accounts Payable, Current $576.00K.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $467.00K 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $374.00K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $347.00K 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $576.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $554.00K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $615.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $314.00K 10-K · filed 2026-03-11 | $713.00K 10-K · filed 2025-03-28 |
| 2024-09-30 | $1.00M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $986.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $1.02M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $832.00K 10-K · filed 2025-03-28 | |
| 2023-09-30 | $476.00K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $301.00K 10-Q · filed 2023-10-05 | |
| 2022-12-31 | $539.00K 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |